NCT03123887View on ClinicalTrials.gov

Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With B-precursor ALL

CompletedOBSERVATIONAL
Enrollment

632

Participants

Timeline

Start Date

July 10, 2015

Primary Completion Date

June 3, 2016

Study Completion Date

October 10, 2016

Conditions
B-precursor Acute Lymphoblastic Leukemia
Interventions
OTHER

salvage therapy

VDC(L)P regimen or High-dose cytarabine based regimen or High-dose methotrexate based regimen or Hyper-CVAD regimen or FLAG (Flu, Ara-C, G-CSF) ± anthracyclines based regimen or Repeated original induction regimen or VDP or other

Trial Locations (1)

150000

Institute of Harbin Hematology Oncology, Harbin

All Listed Sponsors
lead

Harbin Hematology and Oncology Institute

OTHER

NCT03123887 - Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With B-precursor ALL | Biotech Hunter | Biotech Hunter